Draxis announces three-phase research, development strategy, reduces Fibrimage development plans

By Elaine Rigoli

Tampa, Fla., March 27 - Draximage, the radiopharmaceutical division of Draxis Health Inc., has realigned its priorities and has scheduled three new development phases.

In the near term, over the next one to three years, Draximage will focus on developing its own versions of a series of currently marketed significant radiopharmaceutical and imaging products whose patents have expired or are close to expiring, according to a company news release.

In addition, high priority will be given to the continued preparation and submission of marketing approval applications throughout Europe and the rest of the world for products already in the Draximage portfolio and which are approved and sold in North America.

For the medium term, in a three- to five-year horizon, the highest priority opportunity is the continued development of Infection, a product in clinical development for the diagnostic imaging of infection.

Additional medium-term development will focus on new radiopharmaceuticals and non-radioactive medical imaging products, the release said.

For the longer term, Draximage said it will partner with biopharmaceutical companies and academic institutions for the identification and eventual in-licensing of new products and technologies.

Although Fibrimage has met primary endpoints in its phase 3 clinical trial in Canada, further market analysis has shown that new technologies have successfully captured the current deep venous thrombosis indications and there is no longer an economically interesting market opportunity at this time in either the at-risk asymptomatic patient, or those with symptoms.

No significant further work will be conducted in the development of this product for the current indications, but other potential opportunities for this product will be explored, the release said.

Draxis Health, based in Mississauga, Ont., provides sterile products, non-sterile products and radiopharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.